AMAG Pharmaceuticals, Inc.  

(Public, NASDAQ:AMAG)   Watch this stock  
Find more results for AMAG
26.59
-0.31 (-1.15%)
After Hours: 26.50 -0.09 (-0.34%)
Jul 28, 4:01PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 26.05 - 27.09
52 week 17.92 - 70.40
Open 26.79
Vol / Avg. 532,758.00/835,428.00
Mkt cap 991.31M
P/E 147.69
Div/yield     -
EPS 0.18
Shares 34.58M
Beta 0.61
Inst. own 123%
Aug 9, 2016
Q2 2016 AMAG Pharmaceuticals Inc Earnings Release - 9:30AM EDT - Add to calendar
Aug 9, 2016
Q2 2016 AMAG Pharmaceuticals Inc Earnings Call - 8:00AM EDT - Add to calendar
Jun 9, 2016
AMAG Pharmaceuticals Inc at Barclays High Yield Bond & Syndicated Loan Conference - Webcast
Jun 7, 2016
AMAG Pharmaceuticals Inc at Jefferies Healthcare Conference - Webcast
Jun 1, 2016
AMAG Pharmaceuticals Inc Analyst Day - Webcast
May 20, 2016
AMAG Pharmaceuticals Inc Annual Shareholders Meeting (Estimated)
May 19, 2016
AMAG Pharmaceuticals Inc Annual Shareholders Meeting
May 4, 2016
AMAG Pharmaceuticals Inc at Deutsche Bank Health Care Conference - Webcast
May 3, 2016
Q1 2016 AMAG Pharmaceuticals Inc Earnings Release
May 3, 2016
Q1 2016 AMAG Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -6.89% 7.84%
Operating margin 6.81% 24.09%
EBITD margin - 46.79%
Return on average assets -1.22% 1.70%
Return on average equity -3.25% 4.71%
Employees 552 -
CDP Score - -

Address

1100 Winter St
WALTHAM, MA 02451-1427
United States - Map
+1-617-4983300 (Phone)
+1-617-4993361 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.

Officers and directors

Gino Santini Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Frank E. Thomas President, Chief Operating Officer
Age: 46
Bio & Compensation  - Reuters
William K. Heiden Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Edward Myles CPA Chief Financial Officer, Senior Vice President - Finance, Treasurer
Age: 43
Bio & Compensation  - Reuters
Nicholas Grund Executive Vice President, Chief Commercial Officer
Bio & Compensation  - Reuters
Nathan McBride Senior Vice President - Innovation Architects and Chief Information Officer
Bio & Compensation  - Reuters
Joseph Vittiglio Senior Vice President, General Counsel, Secretary
Age: 43
Bio & Compensation  - Reuters
Todd H. Van Horn General Manager - CBR and Senior Vice President - Consumer Marketing & Sales at AMAG
Bio & Compensation  - Reuters
Elizabeth Bolgiano Senior Vice President of Human Resources
Bio & Compensation  - Reuters
Robert M. Brenner M.D. Senior Vice President - Medical Affairs
Age: 45
Bio & Compensation  - Reuters